Beitinjaneh, A. M., Nikiforow, S., Mahadeo, K. M., Chaganti, S., Choquet, S., Derickx, D., … Baiocchi, R. (2026). Impact of Prior Treatment on the Efficacy of Tabelecleucel for Epstein-Barr Virus-Driven Posttransplant Lymphoproliferative Disease: Subgroup Analysis from the phase 3 Allele Study. In TRANSPLANTATION AND CELLULAR THERAPY (Vol. 32).

Beitinjaneh, Amer M., Sarah Nikiforow, Kris Michael Mahadeo, Sridhar Chaganti, Sylvain Choquet, Daan Derickx, Armin Ghobadi, et al. “Impact of Prior Treatment on the Efficacy of Tabelecleucel for Epstein-Barr Virus-Driven Posttransplant Lymphoproliferative Disease: Subgroup Analysis from the phase 3 Allele Study.” In TRANSPLANTATION AND CELLULAR THERAPY, Vol. 32, 2026.

Beitinjaneh AM, Nikiforow S, Mahadeo KM, Chaganti S, Choquet S, Derickx D, et al. Impact of Prior Treatment on the Efficacy of Tabelecleucel for Epstein-Barr Virus-Driven Posttransplant Lymphoproliferative Disease: Subgroup Analysis from the phase 3 Allele Study. In: TRANSPLANTATION AND CELLULAR THERAPY. 2026.

Beitinjaneh, Amer M., et al. “Impact of Prior Treatment on the Efficacy of Tabelecleucel for Epstein-Barr Virus-Driven Posttransplant Lymphoproliferative Disease: Subgroup Analysis from the phase 3 Allele Study.” TRANSPLANTATION AND CELLULAR THERAPY, vol. 32, no. 2, 2026.

Beitinjaneh AM, Nikiforow S, Mahadeo KM, Chaganti S, Choquet S, Derickx D, Ghobadi A, Valenti R, Friedetzky A, Roye S, Reshef R, Prockop SE, Baiocchi R. Impact of Prior Treatment on the Efficacy of Tabelecleucel for Epstein-Barr Virus-Driven Posttransplant Lymphoproliferative Disease: Subgroup Analysis from the phase 3 Allele Study. TRANSPLANTATION AND CELLULAR THERAPY. 2026.